Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11

EMA receives application for marketing authorisation for Lagevrio (molnupiravir) for treating patients with COVID-19

EMA evaluating data on booster dose of COVID-19 Vaccine Janssen

EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19

Monitoring of monoclonal antibodies for COVID-19: weekly report published

EMA starts review of Paxlovid for treating patients with COVID-19

EMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-19

Monitoring of monoclonal antibodies for COVID-19: weekly report published

EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11

COVID-19: EMA and Heads of Medicines Agencies update on molnupiravir

Monitoring of monoclonal antibodies for COVID-19: weekly report published

Opinion of AIFA’s Scientific Technical Commission on the administration of a dose booster of COVID-19 vaccine Janssen

EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly

Monitoring of monoclonal antibodies for COVID-19: weekly report published

AIFA’s Scientific-Technical Committee releases opinion on booster dose administration of Spikevax vaccine against COVID-19

Spikevax: EMA recommendation on booster dose

COVID-19: EMA starts rolling review of molnupiravir

Monitoring of monoclonal antibodies for COVID-19: weekly report published

Aggiornamento delle modalità ottimali d’uso degli anticorpi monoclonali anti COVID-19

EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11